Raolat Abdulai MD, MMSc

From August 2024, Raolat Abdulai, M.D. is the Chief Medical Officer at Galvani Bioelectronics. In her role, she is leading Galvani’s clinical organization encompassing the clinical development, surgical, clinical operations, medical affairs, biostatistics, and disease biology-focused pre-clinical functions as well as the portfolio of current and future clinical studies. She joined Galvani Bioelectronics from Sanofi, where she most recently served as the Global Clinical Lead for dupilumab in Immunology and Inflammation. She played a pivotal role in shaping the clinical strategies for multiple indication expansions across disease areas, most recently with the approval of the first-ever biologic for chronic obstructive pulmonary disease (COPD), focusing on late-stage data to transform treatment paradigms and enhance patient outcomes.

Raolat is a pulmonary and critical care physician with an extensive background in early and late clinical development, digital biomarkers, and technology in clinical operations. Raolat received a B.S. in from the University of Maryland and an M.D. from Howard University. She completed her Internal Medicine training at the Mayo Clinical and her fellowship Pulmonary and Critical Medicine at Harvard Medical School/Brigham and Women’s Hospital. She was also a fellow in the NIH-funded training program and completed her Masters in Medical Science in Biomedical Informatics at Harvard Medical School.